Fordham Law alumna Irena Royzman ’03 has joined Kramer Levin Naftalis & Frankel LLP as a partner in their growing intellectual property litigation practice in New York. She joins them after about 15 years of representing some of the world’s largest pharmaceutical and biotechnology companies at Patterson Belknap Webb & Tyler LLP.
Irena Royzman, who has litigated patent and trademark infringement matters under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act for companies like Janssen Biotech Inc. and Takeda Pharmaceuticals USA Inc., joined Kramer Levin as a partner on June 10 after about 15 years at Patterson Belknap.
Kramer Levin’s track record in trial wins and successes before the Patent Trial and Appeal Board put the firm at the top of Royzman’s list, she told Law360 on Tuesday.
“The firm’s focus on the times and trends really made it attractive,” Royzman said. “There’s a biological revolution going on both as a function of what’s happening in science like gene editing and gene therapy and what has happened as a result of the new regulatory pathways like biosimilar pathways.”
Litigation under the BPCIA is bound to continue expanding, and Kramer Levin is well-placed to meet the demand, Royzman said.